About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

When it comes to medically assisted weight loss, there’s two main schools of thought: either weight loss drugs, like the ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

Ozempic was first approved to treat diabetes in Canada seven years ago. Now the largest study of its kind suggests it and ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

A new study found people with type 2 diabetes who used drugs like Ozempic had a reduced risk of 42 health conditions or ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular ...

Spend a while scrolling through social media and odds are you'll encounter someone sharing their experience with a new fitness or weight loss regimen.